Therapeutic Options in Treatment-Resistant Depression;Behandlungsmöglichkeiten der Therapieresistenten Depression

Journal fur Neurologie, Neurochirurgie und Psychiatrie

Volumn 5, Issue 1, 2004, Pages 28-39

  Leitner, Ingeborg ^a   Bailer, U ^a   Letmaier, M ^a   Stastny, J ^a   Aschauer, H ^a   Kasper, S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Depression; Resistance to antidepressants; Treatment resistant depression

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BROFAROMINE; BUSPIRONE; CARBAMAZEPINE; DESIPRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PEMOLINE; PHENELZINE; PINDOLOL; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; YOHIMBINE;

CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DRUG CLASSIFICATION; ELECTROCONVULSIVE THERAPY; HUMAN; PATIENT COMPLIANCE; PHOTOTHERAPY; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RELAPSE; REVIEW; SLEEP DEPRIVATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; VAGUS NERVE STIMULATION;

EID: 1842430455     PISSN: 16081587     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Morris JB, Beck AT. The efficacy of antidepressant drugs. A review of research (1958-1972). Arch Gen Psychiatry 1974; 30: 667-74.
2. Möller HJ. [Therapy resistance to antidepressive drugs: risk factors and treatment possibilities]. Nervenarzt 1991; 62: 658-69.
3. Schmauss M, Meller I. [Therapy refractory depression - causes and treatment possibilities]. Psychiatr Prax 1989; 16: 101-8.
4. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999; 9: 83-91.
5. Linden M. [Therapeutic strategies for improving patient-compliance (author's transl)]. Nervenarzt 1979; 50: 109-14.
6. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5-43.
7. Nierenberg AA. A systematic approach to treatment-resistent depression. J Clin Psychiatry Monograph 1992; 10: 5-10.
8. Schmauss M, Erfurth A, Scholderle M. Einsatz von Antidepressiva und MAO-Hemmern ins sequentieller Folge oder in Kombination miteinander als effiziente Strategie bei therapieresistenter Depression. In: Möller HJ (ed). Therapieresistenz unter Antidepressiva-Behandlung. Springer, Berlin, Heidelberg, New York, 1990; 127-36.
9. Charney DS, Price LH, Heninger GR. Desipramine-yohimbine combination treatment of refractory depression. Implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch Gen Psychiatry 1986; 43: 1155-61.
10. Reimherr FW, Wood DR, Byerley B, Brainard J, Grosser BI. Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984; 20: 70-2.
11. Cole JO, Schatzberg AF, Sniffin C, Zolner J, Cole JP. Trazodone in treatment resistant depression: an open study. J Clin Psychopharmacol 1981; 1: 49-54.
12. Stern WC, Harto-Truax N, Bauer N. Efficacy of bupropion in tricyclic-resistant or intolerant patients. J Clin Psychiatry 1983; 44: 148-52.
13. McGrath PJ, Stewart JW, Nunes EV, Ocepek-Welikson K, Rabkin JG, Quitkin FM, Klein DF. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993; 150: 118-23.
14. Nolen WA, Haffmans PM, Bouvy PF, Duivenvoorden HJ. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 1993; 28: 189-97.
15. Thase ME, Mallinger AG, Mc Knight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149: 195-8.
16. Beasley CM Jr, Sayler ME, Cunningham GE, Weiss AM, Masica DN. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 1990; 20: 193-200.
17. Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR. The short- and long-term efficacy of paroxetine HCI: B. Data from a double-blind crossover study and from a year-long term trial vs. imipramine and placebo. Psychopharmacol Bull 1989; 25: 272-6.
18. Gagiano CA, Muller PG, Fourie J, Le Roux JF. The therapeutic efficacy of paroxetine: (a) an open study in patients with major depression not responding to antidepressants; (b) a double-blind comparison with amitriptyline in depressed outpatients. Acta Psychiatr Scand 1989 (Suppl); 350: 130-1.
19. Delgado PL, Price LH, Charney DS, Heninger GR. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 1988; 15: 55-60.
20. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Haffmans J. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 1988; 78: 668-75.
21. White K, Wykoff W, Tynes LL, Schneider L, Zemansky M. Fluvoxamine in the treatment of tricyclic-resistant depression. Psychiatr J Univ Oft 1990; 15: 156-8.
22. Brown WA, Harrison W. Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull 1992; 28: 253-6.
23. Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 1996; 57: 67-71.
24. Joffe RT, Levitt AJ, Sokolov ST, Young LT. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996; 57: 114-5.
25. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997; 58: 16-21.
26. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994; 14: 419-23.
27. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry 1999; 175: 12-6.
28. de Montigny C, Silverstone PH, Debonnel G, Blier P, Bakish D. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999; 19: 401-6.
29. Mitchell PB, Schweitzer I, Burrows G, Johnson G, Polonowita A. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol 2000; 20: 483-7.
30. Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, Cohen M. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 2001; 62: 413-20.
31. Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, Mendlewicz J, Möller HJ, Nemeroff CB, Saiz J, Such P, Torta R, Versiani M. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002; 63: 826-37.
32. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50: 387-93.
33. Katona CL, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DR, Lock T, Burns RA, Robertson MM. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166: 80-6.
34. Schopf J, Baumann P, Lemarchand T, Rey M. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. Pharmacopsychiatry 1989; 22: 183-7.
35. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162: 634-40.
36. de Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981; 138: 252-6.
37. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19: 427-34.
38. Bauer M, Bschor T, Kunz D, Berghofer A, Strohle A, Muller-Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000; 157: 1429-35.
39. Prange AJ Jr, Wilson IC, Rabon AM, Lipton MA. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 1969; 126: 457-69.
40. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990; 32: 241-51.
41. Thase ME, Kupfer DJ, Jarrett DB. Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine. J Clin Psychiatry 1989; 50: 385-8.
42. Bauer M, Hellweg R, Graf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 1998; 18: 444-55.
43. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51: 248-51.
44. Tome MB, Isaac MT, Harte R, Holland C. Paroxetine and pindolol: a randomized trial of serolonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997; 12: 81-9.
45. Moreno FA, Gelenberg AJ, Bachar K, Delgado PL. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry 1997; 58: 437-9.
46. Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry 1999; 56: 375-9.
47. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991; 52: 217-20.
48. Bakish D. Fluoxetine potentiation by buspirone: three case histories. Can J Psychiatry 1991; 36: 749-50.
49. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993; 54: 269-71.
50. Fischer P, Tauscher J, Kufferle B, Kasper S. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. Int Clin Psychopharmacol 1998; 13: 83-6.
51. Landen M, Bjorling G, Agren H, Fahlen T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998; 59: 664-8.
52. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60: 256-9.
53. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-4.
54. Pollack MH, Hammerness P. Adjunctive yohimbine for treatment in refractory depression. Biol Psychiatry 1993; 33: 220-1.
55. th Annual Meeting of the American College of Neuropsychopharmacology Waikoloa, Hawaii 1997.
56. Nemets B, Mishory A, Levine J, Belmaker RH. Inositol addition does not improve depression in SSRI treatment failures. J Neural Transm 1999; 106: 795-8.
57. Levine J, Mishori A, Susnosky M, Martin M, Belmaker RH. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biol Psychiatry 1999; 45: 270-3.
58. Cullen M, Mitchell P, Brodaty H, Boyce P, Parker G, Hickie I, Wilhelm K. Carbamazepine for treatment-resistant melancholia. J Clin Psychiatry 1991; 52: 472-6.
59. Schaff MR, Fawcett J, Zajecka JM. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry 1993; 54: 380-4.
60. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990; 147: 431-4.
61. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991; 48: 62-8.
62. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991; 11: 127-32.
63. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996; 57: 72-6.
64. Bader GM, Hawley JM, Short DD. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report. J Clin Psychopharmacol 1998; 18: 255-6.
65. Bouckoms A, Mangini L. Pergolide: an antidepressant adjuvant for mood disorders? Psychopharmacol Bull 1993; 29: 207-11.
66. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000; 61: 378-81.
67. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999; 156: 646-9.
68. Oppenheim G, Zohar J, Shapiro B, Belmaker RH. The role of estrogen in treating resistant depression. In: Zohar J, Belmaker RH (eds). Treating resistant depression. PMA Publishing, New York, 1987; 357-66.
69. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000; 60: 121-30.
70. Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992; 44: 257-62.
71. Kielholz P, Terzani S, Gastpar M. [Management of treatment-resistant depression (author's transl)]. Dtsch Med Wochenschr 1978; 103: 241-43.
72. Weilburg JB, Rosenbaum JF, Biederman J. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989; 50: 447-9.
73. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48: 303-7.
74. Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992; 161: 562-5.
75. Levitt AJ, Joffe RT, Kamil R, McIntyre R. Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination? J Clin Psychiatry 1999; 60: 613-6.
76. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994; 151: 1372-4.
77. Bondolfi G, Chautems C, Rochat B. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of fluvoxamine augmentation. Psychopharmacology (Berl) 1996; 128: 421-5.
78. Hyttel J, Bogeso KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram residues in the (S)-(+)- enantiomer. J Neural Transm Gen Sect 1992; 88: 157-60.
79. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with Mirtazapine. Biol Psychiatry 2002; 51: 183-8.
80. Devarajan S, Dursun SM. Citalopram plus reboxetine in treatment-resistant depression. Can J Psychiatry 2000; 45: 489-490.
81. Schmauss M, Kapfhammer HP, Meyr P, Hoff P. Combined MAO inhibitor and tri-(tetra)cyclic antidepressant treatment in therapy resistant depression. A retrospective study. Pharmacopsychiatry 1986; 19: 251-2.
82. Young JP, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J 1979; 2: 1315-7.
83. White K, Pistole T, Boyd JL. Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study. Am J Psychiatry 1980; 137: 1422-5.
84. Razani J, White KL, White J, Simpson G, Sloane RB, Rebal R, Palmer R. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch Gen Psychiatry 1983; 40: 657-61.
85. White K, Razani J, Simpson G, Rebal R, Sloane RB, O'Leary J, Palmer R. Combined MAOI-tricylic antidepressant treatment: a controlled trial. Psychopharmacol Bull 1982; 18: 180-1.
86. König F, Wolfersdorf M. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression. Pharmacopsychiatry 1997; 30: 93-6.
87. Glassman AH, Platman SR. Potentiation of a monoamine oxidase inhibitor by tryptophan. J Psychiatr Res 1969; 7: 83-8.
88. Shawcross C, Tyrer P. The place of monoamine oxidase inhibitors in the treatment of resistant depression. In: Zohar J, Belmaker H (eds). Treatment resistant depression. PMA Publishing, New York, 1987; 257-68.
89. Walinder J, Skott A, Carlsson A, Nagy A, Bjorn-Erik R. Potentiation of the antidepressant action of clomipramine by tryptophan. Arch Gen Psychiatry 1976; 33: 1384-9.
90. Honore P, Moller SE, Jorgensen A. Lithium + L-tryptophan compared with amitriptyline in endogenous depression. J Affect Disord 1982; 4: 79-82.
91. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-13.
92. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84-112.
93. Kasper S. Schlafentzugstherapie - eine Chance bei Antidepressiva response? In: Möller HJ (ed). Therapieresistenz unter Antidepressiva-Behandlung. Springer, Berlin Heidelberg New York, 1990; 149-65.
94. Bhanji S, Roy GA. The treatment of psychotic depression by sleep deprivation: a replication study. Br J Psychiatry 1975; 127: 222-6.
95. Dessauer M, Goetze U, Tolle R. Periodic sleep deprivation in drug-refractory depression. Neuropsychobiology 1985; 13: 111-6.
96. Nelsen MR, Dunner DL. Treatment resistance in unipolar depression and other disorders. Diagnostic concerns and treatment possibilities. Psychiatr Clin North Am 1993; 16: 541-66.
97. Markowitz J, Brown R, Sweeney J, Mann JJ. Reduced length and cost of hospital stay for major depression in patients treated with ECT. Am J Psychiatry 1987; 144: 1025-9.
98. Solan WJ, Khan A, Avery DH, Cohen S. Psychotic and nonpsychotic depression: comparison of response to ECT. J Clin Psychiatry 1988; 49: 97-9.
99. Sackeim HA. Continuation therapy following ECT: directions for future research. Psychopharmacol Bull 1994; 30: 501-21.
100. Sackeim HA, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S, Fitzsimons L, Moody BJ, Clark J. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry 2000; 57: 425-34.
101. Höflich G, Kasper S, Hufnagel A, Ruhrmann S, Möller HJ. Application of transcranial magnetic stimulation in treatment of drug-resistant major depression: a report of two cases. Hum Psychopharmacol 1993; 8: 361-5.
102. Pascual-Leone A, Rubio B, Pallardo F, Catala MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 1996; 348: 233-7.
103. Padberg F, Zwanzger P, Thoma H, Kathmann N, Haag C, Greenberg BD, Hampel H, Möller HJ. Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. Psychiatry Res 1999; 88: 163-71.
104. Padberg F, Zwanzger P, Keck ME, Kathmann N, Mikhaiel P, Ella R, Rupprecht P, Thoma H, Hampel H, Toschi N, Möller HJ. Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. Neuropsychopharmacology 2002; 27: 638-45.
105. Berman RM, Narasimhan M, Sanacora G, Miano AP, Hoffman RE, Hu XS, Charney DS, Boutros NN. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol Psychiatry 2000; 47: 332-7.
106. Rush AJ, George MS, Sackeim HA, Marangell LB, Husain MM, Giller C, Nahas Z, Haines S, Simpson RK, Jr., Goodman R. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 2000; 47: 276-86.
107. DeRubeis RJ, Gelfand LA, Tang TZ, Simons AD. Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry 1999; 156: 1007-13.
108. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 1989; 46: 971-82.
109. Hollon SD, DeRubeis RJ, Evans MD, Wiemer MJ, Garvey MJ, Grove WM, Tuason VB. Cognitive therapy and pharmacotherapy for depression. Singly and in combination. Arch Gen Psychiatry 1992; 49: 774-81.
110. Hollon SD, Shelton RC, Davis DD. Cognitive therapy for depression: conceptual issues and clinical efficacy. J Consult Clin Psychol 1993; 61: 270-5.
111. Thase ME, Greenhouse JB, Frank E, Reynolds CF, III, Pilkonis PA, Hurley K, Grochocinski V, Kupfer DJ. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997; 54: 1009-15.
112. Paykel ES, Scott J, Teasdale JD. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 1999; 56: 829-35.
113. Fava GA, Savron G, Grandi S, Rafanelli C. Cognitive-behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry 1997; 58: 278-82.
114. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000; 342: 1462-70.
115. Fava GA, Rafanelli C, Grandi S, Canestrari R, Morphy MA. Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998; 155: 1443-5.
116. Lovett LM, Crimmins R, Shaw DM. Outcome in unipolar affective disorder after stereotactic tractotomy. Br J Psychiatry 1989; 155: 547-50.
117. Poynton A, Bridges PK, Bartlett JR. Psychosurgery in Britain now. Br J Neurosurg 1988; 2: 297-306.